Loading data...
Loading data...
Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | ANRO Alto Neuroscience, Inc. | ABBV AbbVie |
|---|---|---|
| Price | $30.27 -2.3% | $263.96 -0.0% |
| StockIQ Score | 46D+ Moderate Risk: Medium | 59C Moderate Risk: High |
| Technical | 29F | 88A |
| Fundamental | 50C- | 57C |
| Growth | 43D | 34F |
| Fair Value | 38F | 33F |
| News | 92A+ | 100A+ |
| Quality | 55C | 42D |
| Risk | 46D+ | 36F |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
Alto Neuroscience (ANRO) outperforms AbbVie (ABBV) in technical strength, scoring 79 compared to 58. However, AbbVie has a slightly better fundamental score at 56 versus ANRO’s 50. Both share a "MODERATE" rating, but ANRO’s higher technical score suggests stronger short-term market momentum, while AbbVie’s higher fundamentals indicate more stable financial health.